© 2018 Miraculo Inc. All Rights Reserved
Cannabinoids are chemicals that are found in the cannabis plant (cannabis sativa). Cannabidiol (CBD) is one of these chemicals and studies have shown it has anti inflammatory effects when induced on animal cells. People have smoked cannabis for thousands of years and it has said have an anti inflammatory role in the body. Tetrahydrocannabinol (THC) is another one of these chemicals and it is said it has psychoactive effects. Cannabinoid receptors (CB1 and CB2) are found in the endocannabinoid system and allow cannabinoids to thrive in the body. This paper will look at how a synthetic cannabinoid can be used in the treatment of spasticity and pain in multiple sclerosis (MS).
Here is the full scientific article if you wish to download it.
Synthetic cannabinoids may alleviate MS treatment in Mice
Theiler murine encephalomyelitis virus–induced demyelinating disease (TMEV-IDD) is a mouse model of chronic-progressive multiple sclerosis (MS) described by demyelination in the central nervous system and spastic hindlimb paralysis. Existing MS therapies decrease relapse rates in 30% of relapsing MS patients, but are not efficient in chronic-progressive disease, and their impacts on disability progression are unknown. Experimental studies demonstrate cannabinoids are useful for symptomatic treatment of spasticity and tremor in MS. Cannabinoids, however, have reported immunosuppressive properties. This paper shows that a cannabinoid receptor agonist can halt progression of clinical disease symptoms in mice with preexisting TMEV-IDD. Clinical trials investigating the therapeutic potential of cannabinoids for the symptomatic treatment of MS are ongoing, and this study demonstrates that they may also have potent immunoregulatory abilities.
Cannabinoids can have a therapeutic effect in MS
In summary, treatment with selective cannabinoid receptor agonists can reduce the progression of established TMEV-IDD. In addition, this agonist may inhibit clinical disease at multiple levels depending upon the stage of disease. During late-stage disease, the selective agonist has no inhibitory effect upon good cell growth. This study promotes preclinical evidence suggesting that cannabinoids may be promising therapeutic agents for treating autoimmune disorders such as MS by exerting potent immunoregulatory effects, in addition to providing symptomatic relief of spasticity, neuropathic pain, and bladder dysfunction.